Welcoming the future: embracing novel technologies for a progressive health system

Abstract

•Novel technologies present novel opportunities in patient care that should be welcomed.•However, studies suggest their reception ranges from the enthusiastic to the reluctant across Europe.•Key to integrating advances into health care depends on keeping patient interests at the forefront.•Major strategic EU reviews over 2024-2025 will impact on health and public spending—positively or negatively.•Focus on equitable access, infrastructure, and governance to deliver tech advancements to patients effectively. BackgroundNovel technologies offer great possibilities for improving patient care, but their adoption varies across different European countries. To successfully integrate these advancements, it is crucial to prioritize patient interests and avoid getting side-tracked by issues that seek to preserve established positions or neglect collaboration. Next-generation sequencing and liquid biopsy in cancer patients hold substantial potential for early diagnosis and reducing suffering, but only if they are effectively implemented into routine health care.MethodsAn examination of the infrastructure and governance requirements in European member states was conducted to identify significant gaps and discrepancies in the readiness to capitalize on the benefits that these technologies can provide.ResultsThese disparities highlight the existing inequalities and missed opportunities within the European Union (EU), which are further exacerbated by varying economic statuses.ConclusionsAs Europe undergoes a comprehensive review of its health policies and public spending between 2024 and 2025, it is an opportune time to prioritize ensuring that patients can access the advancements offered by technology and science. Novel technologies offer great possibilities for improving patient care, but their adoption varies across different European countries. To successfully integrate these advancements, it is crucial to prioritize patient interests and avoid getting side-tracked by issues that seek to preserve established positions or neglect collaboration. Next-generation sequencing and liquid biopsy in cancer patients hold substantial potential for early diagnosis and reducing suffering, but only if they are effectively implemented into routine health care. An examination of the infrastructure and governance requirements in European member states was conducted to identify significant gaps and discrepancies in the readiness to capitalize on the benefits that these technologies can provide. These disparities highlight the existing inequalities and missed opportunities within the European Union (EU), which are further exacerbated by varying economic statuses. As Europe undergoes a comprehensive review of its health policies and public spending between 2024 and 2025, it is an opportune time to prioritize ensuring that patients can access the advancements offered by technology and science.

Ähnliche Arbeiten